SCHEMBL3083698

SCHEMBL3083698

C[C@H]1COCCN1c1cc(N2CCOC[C@@H]2C)nc(N)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.58
ROCK1 Q13464 2/20 0.58
AURKB Q96GD4 2/20 0.58
AURKA O14965 1/20 0.58
ATR Q13535 8/20 0.52
ATRIP Q8WXE1 7/20 0.52
CHEK1 O14757 6/20 0.52
PDCD1 Q15116 6/20 0.52
CD274 Q9NZQ7 6/20 0.52
PIK3CA P42336 8/20 0.49
MTOR P42345 8/20 0.49
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
PIK3R1 P27986 3/20 0.47
PIK3CD O00329 2/20 0.47
PIK3CB P42338 1/20 0.47
PIK3CG P48736 1/20 0.47
RICTOR Q6R327 1/20 0.47
RPTOR Q8N122 1/20 0.47
PIK3C3 Q8NEB9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2448685 0.91 CRHBP (0.61) PDPK1ROCK1AURKBAURKAATR
SCHEMBL1318430 0.90 CYP1A2 (0.60) PDPK1ROCK1AURKBAURKAATR
SCHEMBL1774685 0.85 HRH3 (0.55) PDPK1ROCK1AURKBAURKA
SCHEMBL1775307 0.85 HRH3 (0.55) PDPK1ROCK1AURKBAURKA
SCHEMBL21516848 0.82 CRHBP (0.55) PDPK1ROCK1AURKBAURKAATR
SCHEMBL21516206 0.82 CRHBP (0.55) PDPK1ROCK1AURKBAURKAATR
SCHEMBL3081642 0.81 MTOR (0.54) ATRATRIPCHEK1PDCD1CD274
SCHEMBL3723256 0.81 PDCD1 (0.56) PDPK1ROCK1AURKBAURKAATR
SCHEMBL3723251 0.81 PDCD1 (0.56) PDPK1ROCK1AURKBAURKAATR
SCHEMBL21263111 0.80 ATR (0.53) PDPK1ROCK1AURKBAURKAATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227858-A1 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2010-09-09 US disclosed
US-20100227858-A1 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2010-09-09 US disclosed
US-20100227858-A1 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2010-09-09 US disclosed
WO-2009007751-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227858-A1 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES MTOR, PIK3CA, PIK3CD PDPK1 7/4885ROCK1 1733/4885AURKB 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.